Cargando…

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

SIMPLE SUMMARY: AML is a genetically heterogeneous disease with a median age of diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive chemotherapy. Often, the disease is accompanied by a poor prognosis due to high-risk genetic features or due to antecedent hematol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Maximilian, Schnetzke, Ulf, Hochhaus, Andreas, Scholl, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616498/ https://www.ncbi.nlm.nih.gov/pubmed/34830877 http://dx.doi.org/10.3390/cancers13225722

Ejemplares similares

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
por: Scholl, Sebastian, et al.
Publicado: (2020)

Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
por: Tober, Romy, et al.
Publicado: (2022)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
por: Voigt, Margarete, et al.
Publicado: (2021)

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia
por: Fischer, Mike, et al.
Publicado: (2016)

P474: FUNCTIONAL (PHOSPHO-)PROTEOMICS OF DRUG RESPONSE IN ACUTE MYELOID LEUKEMIA
por: Oliinyk, Denys, et al.
Publicado: (2023)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

A 19-year-old patient with atypical chronic myeloid leukemia
por: Ernst, Philipp, et al.
Publicado: (2020)

Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia
por: Hauptmann, Lisa, et al.
Publicado: (2023)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

A personalized approach to acute myeloid leukemia therapy: current options
por: Illangeswaran, Raveen Stephen Stallon, et al.
Publicado: (2019)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
por: Frietsch, Jochen J., et al.
Publicado: (2022)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia
por: Ferrara, Felicetto, et al.
Publicado: (2019)

Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023
por: Premnath, Naveen, et al.
Publicado: (2023)

Novel therapeutic options in Acute Myeloid Leukemia
por: Medinger, Michael, et al.
Publicado: (2016)

Treatment of toxoplasmosis: Current options and future perspectives
por: Konstantinovic, Neda, et al.
Publicado: (2019)

Current Options and Future Perspectives in the Treatment of Dyslipidemia
por: Muscoli, Saverio, et al.
Publicado: (2022)

Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions
por: Stevens, Alexandra M., et al.
Publicado: (2021)

Current perspectives for the treatment of chronic myeloid leukemia
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

Early Ophthalmological Manifestations of Acute Myeloid Leukemia: Current Perspectives
por: El Salloukh, Nasrine Anais, et al.
Publicado: (2022)

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
por: Pinto-Merino, Álvaro, et al.
Publicado: (2022)

Immune evasion in acute myeloid leukemia: current concepts and future directions
por: Teague, Ryan M, et al.
Publicado: (2013)

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
por: Su, Long, et al.
Publicado: (2022)

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia
por: Eifert, Theresa, et al.
Publicado: (2023)

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
por: Reikvam, Håkon, et al.
Publicado: (2022)

Treatment options for acute myeloid leukemia patients aged <60 years
por: Visani, Giuseppe, et al.
Publicado: (2022)

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
por: Chen, Ying, et al.
Publicado: (2023)

Current treatment for pediatric acute myeloid leukemia
por: Im, Ho Joon
Publicado: (2018)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
por: Talati, Chetasi, et al.
Publicado: (2018)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
por: Maucher, Marius, et al.
Publicado: (2021)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rc1bdi99gek4el3q90jvd7lpmi